Alpha Particles

• 

  Subject Areas on Research

  • (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted α-Particle Radiopharmaceutical Therapy. 
  • 211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y. 
  • A novel silicon array designed for intraoperative charged particle imaging. 
  • Applications of 211At and 223Ra in targeted alpha-particle radiotherapy. 
  • Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy. 
  • Astatine-211: production and availability. 
  • Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. 
  • Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma. 
  • Cytotoxicity of alpha-particle-emitting 5-[211At]astato-2'-deoxyuridine in human cancer cells. 
  • Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia. 
  • Engineered modular recombinant transporters: application of new platform for targeted radiotherapeutic agents to alpha-particle emitting 211 At. 
  • Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry. 
  • High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use. 
  • Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor. 
  • Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images. 
  • Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma. 
  • Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate. 
  • Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. 
  • Radioimmunotherapy with alpha-particle emitting radionuclides. 
  • Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis. 
  • Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At. 
  • Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles. 
  • Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At α-particles. 
  • Radon dosimetry based on the depth distribution of nuclei in human and rat lungs. 
  • Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer. 
  • Targeted Radiotherapy with Alpha-Particle Emitting Radionuclides Seminar, November 18, 2004, Cracow, Poland. 
  • Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. 
  • Targeted therapy using alpha emitters. 
  • Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. 
  • Two approaches for enhancing radioimmunotherapy: alpha emitters and hyperthermia. 
  • Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis. 
• 

  Keywords of People

  • McLendon, Roger Edwin, Professor of Pathology, Pathology